May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation
Author Affiliations & Notes
  • D. Hos
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • F. Bock
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • T. Dietrich
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • J. Onderka
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • F. E. Kruse
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • K. H. Thierauch
    Schering AG, Berlin, Germany
  • C. Cursiefen
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • Footnotes
    Commercial Relationships D. Hos, None; F. Bock, None; T. Dietrich, None; J. Onderka, None; F.E. Kruse, None; K.H. Thierauch, Schering AG, Berlin, E; C. Cursiefen, None.
  • Footnotes
    Support Interdisciplinary Center for Clinical Research (IZKF) Erlangen (A9)
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1696. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K. H. Thierauch, C. Cursiefen; Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1696. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Neovascularisation of the normally avascular cornea is the main risk factor for immune rejections after corneal transplantation and the main sight-threatening complication of a variety of diseases. Purpose of this study was to analyze whether tyrosine kinase inhibitors (TKIs) can inhibit not only hem-, but also lymphangiogenesis, and whether treatment with TKIs after normal-risk corneal transplantation can improve graft survival.

Methods:: Three 11-0 nylon sutures were placed in the corneal stroma of 6 week old Balb/C mice and left in place for 14 days. Meanwhile, one treatment group received the TKI PTK787/ZK 222584 (PTK/ZK; 75 mg/kg, orally, twice a day), the other treatment group received another TKI (ZK 261991: ZK991; 50 mg/kg, orally, twice a day), control mice received equal amounts of the substances' vehicle (both compounds: Schering AG, Berlin). Afterwards, whole mount preparations of the corneas were performed. For immunohistochemistry, LYVE-1 antibody as a specific lymphatic vascular marker and CD-31 as a panendothelial marker were used. The fluorescence microscopic pictures were analyzed morphometrically on digitized whole mounts using analySIS^B® software.Normal-risk allogeneic (C57BL/6 to Balb/C) corneal transplantations were performed. The treatment group received the TKI ZK991 (50 mg/kg, orally, twice a day, for 2 weeks), the control group received an equal amount of the substances' vehicle. Corneal sutures were removed after 7 days, grafts were then examined once a week for 8 weeks microscopically and were scored clinically (as previously described).

Results:: Treatment with TKIs resulted in a significant reduction of neovascularisation. In comparison to controls, hemangiogenesis was inhibited by 26% (PTK/ZK; p=0.0006) and 50% (ZK991; p<0.0001), lymphangiogenesis was inhibited by 61% (PTK/ZK; p<0.0001) and 76% (ZK991; p<0.0001). Comparing the survival proportions after corneal transplantation, treatment with ZK991 significantly improved the graft survival rate (survival rates: ZK991: 68%; control: 33%; p=0.0167).

Conclusions:: Receptor tyrosine kinases seem to play a functional and pivotal role in mediating inflammatory neovascularisation. Therefore, TKIs are potent inhibitors of hem- and lymphangiogenesis in the cornea, and TKIs may be used to promote corneal graft survival after corneal transplantation.

Keywords: neovascularization • transplantation • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×